These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32827442)

  • 1. Keeping the Pharmacology in Pharmacoepidemiology.
    Staffa JA
    Clin Pharmacol Ther; 2021 Jun; 109(6):1393-1394. PubMed ID: 32827442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From a Viewpoint of Clinical Settings: Pharmacoepidemiology as Reverse Translational Research (rTR)].
    Kawakami J
    Yakugaku Zasshi; 2017; 137(6):681-683. PubMed ID: 28566573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
    Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
    Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of pharmacovigilance: a personal view.
    Edwards IR
    Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving postapproval drug safety surveillance: getting better information sooner.
    Hennessy S; Strom BL
    Annu Rev Pharmacol Toxicol; 2015; 55():75-87. PubMed ID: 25292435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
    Lu CY
    Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs.
    Lapeyre-Mestre M; Montastruc F
    Therapie; 2019 Apr; 74(2):209-214. PubMed ID: 30792079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoepidemiology: an another kind of drug surveillance].
    Pariente A
    Bull Acad Natl Med; 2015; 199(2-3):275-9. PubMed ID: 27476309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoepidemiology: a new discipline.
    Lawson DH
    Br Med J (Clin Res Ed); 1984 Oct; 289(6450):940-1. PubMed ID: 6435731
    [No Abstract]   [Full Text] [Related]  

  • 11. The utilization and challenges of Japan's MID-NET
    Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoepidemiology and gastroenterology: a close couple.
    Leufkens HG
    Scand J Gastroenterol Suppl; 2000; (232):105-8. PubMed ID: 11232486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety in relation to efficacy: the view of a clinical pharmacologist.
    Sjöqvist F
    Pharmacol Toxicol; 2000; 86 Suppl 1():30-2. PubMed ID: 10905752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of epidemiology to the study of drugs.
    Porta MS; Hartzema AG
    Drug Intell Clin Pharm; 1987 Sep; 21(9):741-7. PubMed ID: 3308393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepidemiology: current status, prospects, and problems.
    Strom BL; Tugwell P
    Ann Intern Med; 1990 Aug; 113(3):179-81. PubMed ID: 2197907
    [No Abstract]   [Full Text] [Related]  

  • 17. How to ascertain drug safety in the context of benefit. Controversies and concerns.
    Simon LS; Strand CV; Boers M; Brooks PM; Tugwell PS; Bombardier C; Fries JF; Henry D; Goldkind L; Guyatt G; Laupacis A; Lynd L; Macdonald T; Mamdani M; Moore A; Saag KG; Silman AJ; Stevens R; Tyndall A
    J Rheumatol; 2009 Sep; 36(9):2114-21. PubMed ID: 19738223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who is now responsible for discovering and warning about adverse effects of generic drugs?
    Kesselheim AS; Green MD; Avorn J
    JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
    [No Abstract]   [Full Text] [Related]  

  • 19. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods in pharmacoepidemiology.
    Sommet A; Pariente A
    Therapie; 2019 Apr; 74(2):187-197. PubMed ID: 30819408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.